SK287495B6 - Rádiofarmaceutiká na diagnostikovanie Alzheimerovej choroby - Google Patents

Rádiofarmaceutiká na diagnostikovanie Alzheimerovej choroby Download PDF

Info

Publication number
SK287495B6
SK287495B6 SK547-2003A SK5472003A SK287495B6 SK 287495 B6 SK287495 B6 SK 287495B6 SK 5472003 A SK5472003 A SK 5472003A SK 287495 B6 SK287495 B6 SK 287495B6
Authority
SK
Slovakia
Prior art keywords
chloro
benzyl
fluoro
phenyl
formula
Prior art date
Application number
SK547-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK5472003A3 (en
Inventor
Christoph-Stephan Hilger
Bernd Johannsen
J�Rg Steinbach
Peter M�Ding
Meredith Halks-Miller
Richard Horuk
Harald Dinter
Raju Mohan
Joseph E. Hesselgesser
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of SK5472003A3 publication Critical patent/SK5472003A3/sk
Publication of SK287495B6 publication Critical patent/SK287495B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SK547-2003A 2000-11-06 2001-11-01 Rádiofarmaceutiká na diagnostikovanie Alzheimerovej choroby SK287495B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24629900P 2000-11-06 2000-11-06
PCT/EP2001/012607 WO2002036581A1 (en) 2000-11-06 2001-11-01 Radiopharmaceuticals for diagnosing alzheimer's disease

Publications (2)

Publication Number Publication Date
SK5472003A3 SK5472003A3 (en) 2003-10-07
SK287495B6 true SK287495B6 (sk) 2010-12-07

Family

ID=22930075

Family Applications (1)

Application Number Title Priority Date Filing Date
SK547-2003A SK287495B6 (sk) 2000-11-06 2001-11-01 Rádiofarmaceutiká na diagnostikovanie Alzheimerovej choroby

Country Status (29)

Country Link
US (2) US6676926B2 (zh)
EP (1) EP1332138B1 (zh)
JP (1) JP4234425B2 (zh)
KR (1) KR20030045167A (zh)
CN (1) CN1473158A (zh)
AR (1) AR035366A1 (zh)
AT (1) ATE314354T1 (zh)
AU (2) AU1403402A (zh)
BG (1) BG107762A (zh)
BR (1) BR0115150A (zh)
CA (1) CA2424598A1 (zh)
DE (1) DE60116365T2 (zh)
EA (1) EA006199B1 (zh)
EE (1) EE200300216A (zh)
HR (1) HRP20030459A2 (zh)
HU (1) HUP0301710A3 (zh)
IL (1) IL155191A0 (zh)
JO (1) JO2207B1 (zh)
MX (1) MXPA03003759A (zh)
NO (1) NO20032007L (zh)
NZ (1) NZ525303A (zh)
PE (1) PE20020531A1 (zh)
PL (1) PL361631A1 (zh)
SK (1) SK287495B6 (zh)
TW (1) TWI238820B (zh)
UY (1) UY27003A1 (zh)
WO (1) WO2002036581A1 (zh)
YU (1) YU33203A (zh)
ZA (1) ZA200304409B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
BR0213452A (pt) 2001-10-22 2004-11-09 Pfizer Prod Inc Derivados de piperazina com atividade antagonista receptora de ccr1
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
PL1620373T3 (pl) * 2003-05-07 2008-09-30 Bayer Schering Pharma Ag Urządzenie i sposób fluorowania nukleofilowego
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
AU2005216949B2 (en) * 2004-02-24 2011-09-22 The General Hospital Corporation Catalytic radiofluorination
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
ES2399147T3 (es) 2006-09-08 2013-03-26 Rhode Island Hospital Tratamiento, prevención y reversión de una enfermedad hepática alcohólica
JP2010502719A (ja) 2006-09-08 2010-01-28 ロード アイランド ホスピタル アルコール誘発性脳疾患の治療、予防および回復
CN101563305A (zh) * 2006-12-21 2009-10-21 哈默史密斯网上成像有限公司 放射性标记方法
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
JP2011502966A (ja) * 2007-10-31 2011-01-27 アルセレス ファーマシューティカルズ， インコーポレイテッド ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法
MX2010010314A (es) 2008-03-21 2011-04-12 Gen Hospital Corp Compuestos y composiciones para la deteccion y el tratamiento de la enfermedad de alzheimer y trastornos relacionados.
EP2161256A1 (en) * 2008-09-08 2010-03-10 Atomic Energy Council - Institute of Nuclear Energy Research Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
WO2011041470A2 (en) * 2009-09-30 2011-04-07 Mallinckrodt Inc. Sustained-release opiate and opiate derivative compositions
TW201201846A (en) * 2010-02-08 2012-01-16 Bayer Schering Pharma Ag Iodo precursor for a PET imaging agent of amyloid plaques
WO2011110511A1 (en) * 2010-03-11 2011-09-15 Bayer Pharma Aktiengesellschaft Spect imaging agents of amyloid plaques
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
EP4321165A2 (en) 2013-12-27 2024-02-14 National University Corporation Tokyo Medical and Dental University Method for diagnosis of alzheimer's disease and frontotemporal lobar degeneration, diagnostic agent, therapeutic agent, and screening method for said agents
US10137211B2 (en) 2015-08-28 2018-11-27 Chdi Foundation, Inc. Probes for imaging Huntingtin protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510021A (ja) 1991-03-13 1994-11-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミネソタ アルツハイマー病検出用の放射性薬剤
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
GB9413772D0 (en) 1994-07-08 1994-08-24 Wyeth John & Brother Ltd 5-HT1A ligands
AU2680797A (en) * 1996-04-24 1997-11-12 Emory University Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
EE200100502A (et) 1999-03-26 2002-12-16 Astrazeneca Ab Ühendid
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer

Also Published As

Publication number Publication date
KR20030045167A (ko) 2003-06-09
EP1332138A1 (en) 2003-08-06
MXPA03003759A (es) 2003-07-28
UY27003A1 (es) 2002-07-31
PL361631A1 (en) 2004-10-04
TWI238820B (en) 2005-09-01
DE60116365D1 (de) 2006-02-02
AU1403402A (en) 2002-05-15
HUP0301710A3 (en) 2007-03-28
US20020131932A1 (en) 2002-09-19
US6676926B2 (en) 2004-01-13
PE20020531A1 (es) 2002-06-15
US6872381B1 (en) 2005-03-29
JP2004513123A (ja) 2004-04-30
BG107762A (en) 2004-03-31
EA006199B1 (ru) 2005-10-27
AR035366A1 (es) 2004-05-12
JP4234425B2 (ja) 2009-03-04
EE200300216A (et) 2003-08-15
EP1332138B1 (en) 2005-12-28
YU33203A (sh) 2006-05-25
JO2207B1 (en) 2004-10-07
NZ525303A (en) 2004-10-29
DE60116365T2 (de) 2006-08-24
SK5472003A3 (en) 2003-10-07
IL155191A0 (en) 2003-11-23
CA2424598A1 (en) 2002-05-10
HRP20030459A2 (en) 2005-04-30
CN1473158A (zh) 2004-02-04
NO20032007L (no) 2003-07-02
AU2002214034B2 (en) 2006-01-05
EA200300507A1 (ru) 2003-12-25
WO2002036581A1 (en) 2002-05-10
BR0115150A (pt) 2003-12-30
ZA200304409B (en) 2004-09-06
ATE314354T1 (de) 2006-01-15
NO20032007D0 (no) 2003-05-05
HUP0301710A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
SK287495B6 (sk) Rádiofarmaceutiká na diagnostikovanie Alzheimerovej choroby
AU2002214034A1 (en) Radiopharmaceuticals for diagnosing alzheimer's disease
TWI245764B (en) Amyloid plaque aggregation inhibitors and diagnostic imaging agents
US8168800B2 (en) Aβ-binding small molecules
CA2924360A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
BRPI0113470B1 (pt) Composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal
CA2438032A1 (en) Benzothiazole derivative compounds, compositions and uses
JPH11514368A (ja) ドーパミン及びセロトニン輸送体リガンド並びにイメージング剤
CN113710286A (zh) 具有改善的组织特异性的前列腺特异性膜抗原(psma)配体
KR100745445B1 (ko) 종양 영상화 화합물
EP2139481B1 (en) 1-[(2'-substituted)-piperazin-1'-yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents
EP2280915A1 (de) Neue ýf-18¨-markierte l-glutaminsäure- und l-glutaminderivative (ii), ihre verwendung sowie verfahren zu ihrer herstellung
EP2711026A1 (en) Radioactive fluorine-labeled quinoxaline compound
EP1175388B1 (en) Spect imaging agents for serotonin transporters
CA2911307C (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
EP4122500A1 (en) Thrombus imaging radiopharmaceutical and composition
US20140348748A1 (en) Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof
WO2021026429A1 (en) Butyrylcholinesterase compounds and use in diseases of the nervous system

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20111101